A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Exclusion Criteria

• •Radiographic measurable disease by RECIST criteria
• •Life expectancy of greater than 4 months and ECOG Performance Status of less than or equal to 2
• •Patients must be an appropriate candidate for the standard combination of cisplatin and etoposide for SCLC. There are no restrictions on radiotherapy
• •No prior chemotherapy for SCLC cancer
• •Participants must meet the hematological, renal and hepatic function requirements outlined in the protocol
• •If brain or bone metastases are present at the time of initial diagnosis, patients must have completed radiation treatment at least 2 weeks before starting the study
• •No active uncontrolled infection
• •No other serious illness or medical condition that in the opinion of the investigator would be expected to interfere with the subject's ability to receive study treatment or comply with study procedures
• •New (defined as 6 months or less) or symptomatic thrombosis at the time of enrollment
• •Indication for anticoagulant treatment such as mechanical heart valves, atrial fibrillation, or previous VTE
• •Contraindication or known hypersensitivity to LMWH or unfractionated heparin (UFH)
• •Active bleeding disorder
• •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Pregnant or breast feeding women